Trial Profile
A Randomized, Double Blind, Placebo Controlled, Study To Compare The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Doses Of Intravenous Administration Of QAX576 In Controlled Or Partially Controlled Asthma Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Dectrekumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Novartis
- 21 Jan 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jul 2009 New trial record